Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies

Expert Opinion on Pharmacotherapy
Federica TomaoPierluigi Benedetti Panici

Abstract

The objective of this review is to summarize results from clinical trials that tested cytotoxic drugs and target strategies for the treatment of platinum resistant (PR) recurrent ovarian cancer (ROC) with particular attention to Phase III and ongoing trials. Areas covered: Since platinum free interval (PFI) represents the most important predictive factor for response to platinum re-treatment in ROC, non-platinum regimens are conventionally considered the most appropriate approaches. Impressive progress has been made in recent decades, resulting in the identification of most effective cytotoxic agents and in the development of new target strategies. However, the efficacy of most of these drugs for the treatment of PR disease is still limited. Expert opinion: The most favorable benefit for the treatment of PR disease, has been described by the AURELIA trial that showed a 3.3 months increase in progression free survival (PFS) when bevacizumab was combined with non-platinum single agent chemotherapy in bevacizumab-naïve patients. Nevertheless, the use of novel agents is associated to important costs for just little gains in survival. Thus, in our opinion the economic evaluation, such as the incorporation of quality of life into the...Continue Reading

References

Feb 22, 1979·Nature·P B SchiffS B Horwitz
Dec 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E A EisenhauerN Colombo
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W ten Bokkel HuininkJ F Heron
Feb 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P G RoseH D Homesley
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A N GordonA J Lacave
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paula M FracassoJames S Hoffman
Oct 29, 2004·Nature Reviews. Cancer·Nicholas TurnerAlan Ashworth
Jul 3, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David G MutchAngeles Alvarez Secord
Sep 15, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·J J KavanaghM A Morgan
Jan 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Agustin A GarciaAmit M Oza
Feb 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gabriella FerrandinaGiovanni Scambia
Jul 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jalid SehouliWerner Lichtenegger
Oct 2, 2009·Lancet·Bryan T HennessyMaurie Markman
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ursula A MatulonisRichard T Penson
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Koen De GeestWilliam E Richards
Jan 14, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christina M AnnunziataElise C Kohn
Mar 5, 2010·Nature Reviews. Cancer·Michèle RouleauGuy G Poirier
Apr 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter C FongStan B Kaye
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bradley J MonkAndrés M Poveda
Jun 30, 2010·Gynecologic Oncology·Michael FriedlanderJoanne J Lager
Aug 14, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J J BiagiE A Eisenhauer
Sep 18, 2010·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Stephen A WelchAmit M Oza
Nov 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniela MateiMichael J Birrer
May 6, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Nicoletta Colombo
May 6, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Gavin C E StuartUNKNOWN Gynecologic Cancer Intergroup
Aug 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonathan A LedermannGordon Rustin
Nov 8, 2011·Critical Reviews in Oncology/hematology·Filippo BellatiMarianna Nuti
Mar 14, 2012·Investigative Ophthalmology & Visual Science·Jonathan D OlinerAngela Coxon
Mar 19, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Pujade-LauraineIsabelle Ray-Coquard

❮ Previous
Next ❯

Citations

Sep 5, 2019·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Lianqiao QiaoXiaowei Xi
Nov 30, 2019·Experimental and Therapeutic Medicine·Hanxue Zou, Hongxia Li
Apr 15, 2019·Cancer Chemotherapy and Pharmacology·Mayumi Kobayashi-KatoKenji Tamura
Oct 13, 2020·Frontiers in Endocrinology·Bastian CzogallaFabian Trillsch
Sep 22, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David E GerberHoward A Burris
Jun 15, 2019·Cell Calcium·Sana KoubaMarie Potier-Cartereau
Feb 23, 2019·Inorganic Chemistry·Chilaluck C KonkankitJustin J Wilson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Expert Opinion on Emerging Drugs
Amanda L JacksonThomas J Herzog
Duodecim; lääketieteellinen aikakauskirja
Ulla Puistola, Arto Leminen
Expert Review of Anticancer Therapy
Emmanouel Saloustros, Vassilis Georgoulias
EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [et Al.]
Nicoletta Colombo
© 2022 Meta ULC. All rights reserved